PL3478719T3 - Stosowanie przeciwciał przeciw sklerostynie w leczeniu wrodzonej łamliwości kości - Google Patents
Stosowanie przeciwciał przeciw sklerostynie w leczeniu wrodzonej łamliwości kościInfo
- Publication number
- PL3478719T3 PL3478719T3 PL17823190T PL17823190T PL3478719T3 PL 3478719 T3 PL3478719 T3 PL 3478719T3 PL 17823190 T PL17823190 T PL 17823190T PL 17823190 T PL17823190 T PL 17823190T PL 3478719 T3 PL3478719 T3 PL 3478719T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- antibodies against
- bone fragility
- congenital bone
- against sclerostin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437353P | 2016-12-21 | 2016-12-21 | |
| EP17823190.8A EP3478719B3 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| PCT/GB2017/053850 WO2018115880A1 (en) | 2016-12-21 | 2017-12-21 | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL3478719T3 true PL3478719T3 (pl) | 2021-10-25 |
| PL3478719T6 PL3478719T6 (pl) | 2025-01-27 |
Family
ID=60915566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17823190.8T PL3478719T6 (pl) | 2016-12-21 | 2017-12-21 | Stosowanie przeciwciał przeciw sklerostynie w leczeniu wrodzonej łamliwości kości |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20200179509A1 (pl) |
| EP (2) | EP3478719B3 (pl) |
| JP (3) | JP7050335B2 (pl) |
| KR (3) | KR20190096409A (pl) |
| CN (2) | CN117442720A (pl) |
| AU (1) | AU2017381433B2 (pl) |
| BR (1) | BR112019012731A2 (pl) |
| CA (1) | CA3047221A1 (pl) |
| CL (1) | CL2019001749A1 (pl) |
| CY (1) | CY1124238T1 (pl) |
| DK (1) | DK3478719T6 (pl) |
| ES (1) | ES2862922T7 (pl) |
| FI (1) | FI3478719T6 (pl) |
| HR (1) | HRP20210207T4 (pl) |
| HU (1) | HUE053436T2 (pl) |
| IL (1) | IL267430B2 (pl) |
| LT (1) | LT3478719T (pl) |
| MX (1) | MX2019007161A (pl) |
| NZ (1) | NZ754676A (pl) |
| PL (1) | PL3478719T6 (pl) |
| PT (1) | PT3478719T (pl) |
| SI (1) | SI3478719T2 (pl) |
| WO (1) | WO2018115880A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| ES2862922T7 (en) * | 2016-12-21 | 2025-02-26 | Mereo Biopharma 3 Ltd | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| CN119241705A (zh) | 2018-03-30 | 2025-01-03 | 安姆根有限公司 | C末端抗体变体 |
| CN112585128B (zh) | 2018-06-18 | 2023-02-21 | 詹森药业有限公司 | 作为malt1抑制剂的吡唑衍生物 |
| EP3953345B1 (en) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Pyridine rings containing derivatives as malt1 inhibitors |
| KR102472582B1 (ko) * | 2020-08-20 | 2022-11-30 | 한림대학교 산학협력단 | 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법 |
| US20250011407A1 (en) * | 2021-09-30 | 2025-01-09 | Mereo Biopharma 3 Limited | Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta |
| WO2025212547A1 (en) * | 2024-04-05 | 2025-10-09 | Amgen Inc. | Methods of treating osteogenesis imperfecta |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| DE69942782D1 (de) | 1998-11-27 | 2010-10-28 | Ucb Sa | Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| EP1636270B1 (en) | 2003-06-16 | 2016-07-20 | UCB Pharma S.A. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US7592429B2 (en) * | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| MY149129A (en) * | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| AR075715A1 (es) * | 2009-03-05 | 2011-04-20 | Novartis Ag | Formulacion de anticuerpo liofilizado |
| US20130138221A1 (en) * | 2010-04-16 | 2013-05-30 | Novartis Ag | Methods and compositions for improving implant osseointegration |
| JP6013915B2 (ja) * | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| MA41142A (fr) * | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| WO2018115879A1 (en) * | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| ES2862922T7 (en) * | 2016-12-21 | 2025-02-26 | Mereo Biopharma 3 Ltd | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
-
2017
- 2017-12-21 ES ES17823190T patent/ES2862922T7/es active Active
- 2017-12-21 EP EP17823190.8A patent/EP3478719B3/en active Active
- 2017-12-21 EP EP21152251.1A patent/EP3868780A1/en active Pending
- 2017-12-21 CA CA3047221A patent/CA3047221A1/en active Pending
- 2017-12-21 HU HUE17823190A patent/HUE053436T2/hu unknown
- 2017-12-21 LT LTEP17823190.8T patent/LT3478719T/lt unknown
- 2017-12-21 CN CN202311429543.0A patent/CN117442720A/zh active Pending
- 2017-12-21 NZ NZ754676A patent/NZ754676A/en unknown
- 2017-12-21 FI FIEP17823190.8T patent/FI3478719T6/fi active
- 2017-12-21 IL IL267430A patent/IL267430B2/en unknown
- 2017-12-21 KR KR1020197021162A patent/KR20190096409A/ko not_active Ceased
- 2017-12-21 JP JP2019533586A patent/JP7050335B2/ja active Active
- 2017-12-21 CN CN201780087087.2A patent/CN110325548B/zh active Active
- 2017-12-21 BR BR112019012731-3A patent/BR112019012731A2/pt unknown
- 2017-12-21 PT PT178231908T patent/PT3478719T/pt unknown
- 2017-12-21 HR HRP20210207TT patent/HRP20210207T4/hr unknown
- 2017-12-21 US US16/469,915 patent/US20200179509A1/en not_active Abandoned
- 2017-12-21 DK DK17823190.8T patent/DK3478719T6/da active
- 2017-12-21 KR KR1020227011791A patent/KR20220051269A/ko not_active Ceased
- 2017-12-21 KR KR1020247023410A patent/KR20240113615A/ko not_active Ceased
- 2017-12-21 WO PCT/GB2017/053850 patent/WO2018115880A1/en not_active Ceased
- 2017-12-21 AU AU2017381433A patent/AU2017381433B2/en active Active
- 2017-12-21 SI SI201730627T patent/SI3478719T2/sl unknown
- 2017-12-21 MX MX2019007161A patent/MX2019007161A/es unknown
- 2017-12-21 PL PL17823190.8T patent/PL3478719T6/pl unknown
-
2019
- 2019-06-21 CL CL2019001749A patent/CL2019001749A1/es unknown
-
2020
- 2020-01-02 US US16/733,144 patent/US20200123242A1/en not_active Abandoned
- 2020-12-30 US US17/138,691 patent/US20210253684A1/en not_active Abandoned
-
2021
- 2021-04-02 CY CY20211100286T patent/CY1124238T1/el unknown
- 2021-12-10 JP JP2021200994A patent/JP2022046529A/ja active Pending
-
2023
- 2023-04-07 US US18/297,280 patent/US20230365669A1/en not_active Abandoned
-
2024
- 2024-05-20 US US18/669,337 patent/US20240400666A1/en active Pending
- 2024-10-11 JP JP2024179475A patent/JP2025020150A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3478719T3 (pl) | Stosowanie przeciwciał przeciw sklerostynie w leczeniu wrodzonej łamliwości kości | |
| IL269371A (en) | Treatment methods | |
| LT3661514T (lt) | Mavakamtenas, skirtas naudoti gydant hipertrofinę kardiomiopatiją | |
| PT3785717T (pt) | Métodos para o tratamento de infeções por coronaviridae | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| LT3472153T (lt) | Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme | |
| PT3562486T (pt) | Uso de dexmedetomidina sublingual para o tratamento da agitação | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| KR102068915B9 (ko) | 조직 인자 경로 억제제 항체 및 그의 용도 | |
| PL3493812T3 (pl) | Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3570940T3 (da) | Pridopidin til anvendelse i behandling af fragilt x-syndrom | |
| PL3236960T3 (pl) | Fluralaner do zastosowania w leczeniu demodekozy | |
| DK3576738T3 (da) | Gaboxadolmonohydrat i behandling af tinnitus | |
| LT3592355T (lt) | Kx2-391/kx-01, skirtas naudoti aktininės keratozės gydymui | |
| PL3732294T3 (pl) | Tymohydrochinon do stosowania w leczeniu hiperglikemii | |
| PL3432872T3 (pl) | Eflornityna do zastosowania w leczeniu nawracającego/opornego na leczenie temozolomidem gwiaździaka anaplastycznego | |
| IL256000A (en) | Quantifying her 2 protein for optimal cancer therapy | |
| HUE063528T2 (hu) | Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére | |
| IL282041A (en) | Egfr inhibitors for treating keratodermas | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| EP3493823C0 (en) | POSTBIOTIC BASED COMPOUND FOR THE TREATMENT OF OCULAR INFLAMMATION |